Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.77 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354243 | 1.00 | CSNK2A1 (0.77) | CSNK2A1CHRNB2CHRNA7CHRNA4GPR84 | |
| SCHEMBL6628604 | 0.89 | CSNK2A1 (0.62) | CSNK2A1CHRNB2CHRNA7CHRNA4GPR84 | |
| SCHEMBL2005588 | 0.87 | CSNK2A1 (1.00) | CSNK2A1GPR84HTR2ATRPM8HTR2C | |
| SCHEMBL22122400 | 0.84 | CHRNB2 (0.60) | CSNK2A1CHRNB2CHRNA7CHRNA4GPR84 | |
| SCHEMBL27929613 | 0.80 | GPR84 (0.72) | CSNK2A1CHRNB2CHRNA7CHRNA4GPR84 | |
| SCHEMBL29352833 | 0.80 | GPR84 (0.67) | CSNK2A1GPR84HTR2ATRPM8HTR2C | |
| SCHEMBL15074715 | 0.80 | HTR2A (0.59) | CSNK2A1CHRNB2CHRNA7CHRNA4GPR84 | |
| SCHEMBL1242939 | 0.80 | GPR84 (0.67) | CSNK2A1GPR84HTR2ATRPM8HTR2C | |
| SCHEMBL273402 | 0.80 | CSNK2A1 (0.57) | CSNK2A1GPR84CYP2A6HTR2AIMPDH2 | |
| SCHEMBL18708142 | 0.80 | CSNK2A1 (0.57) | CSNK2A1CHRNB2CHRNA7CHRNA4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| CN-108341799-B | Novel indole derivatives for the treatment of cancer, viral infections and lung diseases | 生物控制术公司 | 2022-01-25 | — | — | CN | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2020-12-01 | — | — | US | disclosed |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2020-12-01 | — | — | US | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2019-06-06 | — | — | US | disclosed |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2019-06-06 | — | — | US | disclosed |
| EP-2928864-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | Biokinesis (FR) | 2015-10-14 | — | — | EP | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014113485-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014086964-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | BIOKINESIS (FR) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086964-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | BIOKINESIS (FR) | 2014-06-12 | — | — | WO | disclosed |
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | CSNK2A1 606/4885CHRNB2 2182/4885CHRNA7 2170/4885 |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | CSNK2A1 2206/4885CHRNB2 1742/4885CHRNA7 1275/4885 |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | CSNK2A1 250/4885CHRNB2 1698/4885CHRNA7 3637/4885 |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | CSNK2A1 129/4885CHRNB2 4741/4885CHRNA7 4777/4885 |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | IDO2, IDO1, ING2 | CSNK2A1 228/4885CHRNB2 2039/4885CHRNA7 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.